{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["130(15)"],"submitter":["Verstovsek S"],"funding":["NCI NIH HHS"],"journal":["Blood"],"pagination":["1768-1771"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5639482"],"repository":["biostudies-literature"],"pubmed_title":["Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results."],"pmcid":["PMC5639482"],"funding_grant_id":["P30 CA016672"],"pubmed_authors":["Zhen H","Granier M","Cazzola M","Rambaldi A","Pieri L","Assad A","Kantarjian HM","Gattoni E","Rumi E","Vannucchi AM","Verstovsek S","Passamonti F","Barbui T","Barosi G"],"additional_accession":[]},"is_claimable":false,"name":"Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.","description":null,"dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Oct","modification":"2025-04-18T19:03:59.232Z","creation":"2025-04-07T06:44:16.337Z"},"accession":"S-EPMC5639482","cross_references":{"pubmed":["28827411"],"doi":["10.1182/blood-2017-02-765032"]}}